Chris Cutie, M.D.

Bio:

Chris Cutie is Vice President and Disease Area Leader for Bladder Cancer at Johnson & Johnson Innovative Medicine. He is responsible for shaping the scientific strategy required to deliver a broad portfolio of bladder cancer therapies, while building a robust pipeline of next-generation compounds. Chris joined Johnson & Johnson through the TARIS Biomedical Acquisition in 2019. He is a board-certified urologist and holds an MD from Yale and an MBA from Harvard, with surgical and oncology training at MGH/Harvard Medical School. Chris leads efforts to advance innovative therapies in bladder cancer, aiming to transform treatment for patients worldwide.